Thyrocare Tech. Q1 FY27 Earnings Call — Analysis (NSE: THYROCARE)
Thyrocare Q1 FY27 revenue up 24% YoY to ₹240 Cr, PAT up 34% YoY to ₹51.3 Cr; franchisee base crosses 11,700 and specialty diagnostics goes live
The take
Q1FY27 Consolidated Revenue ₹240 Cr ( +24.3% YoY ) . New guidance — FY27 fy27 consolidated revenue growth mid-to-high teens . New story: Franchisee network scaling .
Results
Consolidated revenue ₹240 Cr +24.3% YoY; standalone pathology revenue ₹225.6 Cr +26.1% YoY; EBITDA margin 32.2%, EBITDA up 34% YoY; PAT ₹51.3 Cr +34% YoY; gross margin expanded 290bps to 74.1%
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹240 Cr | +24.3% | yoy · Q1FY27 |
| Standalone Revenue | ₹225.6 Cr | +26.1% | yoy · Q1FY27 |
| EBITDA Margin | 32.2% | point_in_time · Q1FY27 | |
| PAT | ₹51.3 Cr | +34% | yoy · Q1FY27 |
| PAT Margin | 21.4% | point_in_time · Q1FY27 | |
| Gross Margin | 74.1% | +290bps | yoy · Q1FY27 |
| Test Volume Growth | 28% | +28% | yoy · Q1FY27 |
| Franchisee Revenue Growth | 27% | +27% | yoy · Q1FY27 |
| Partnership Revenue Growth | 26% | +26% | yoy · Q1FY27 |
| Active Franchisees | 11,700 | point_in_time · Q1FY27 · end of Q1FY27 |
Guidance
Full-year FY27 revenue growth guidance maintained at mid-to-high teens despite strong Q1; franchisee net adds seen at ~1,700 for the year
What management committed to
- Management expects consolidated revenue growth for FY27 to be in the mid-to-high teens range (~15-19%) compared to FY26 — mid-to-high teens, FY27
- Thyrocare expects to add approximately 1,700 net new franchisees in FY27 (after accounting for churn), with quarterly net adds of 500-700 except in Q3 — 1,700, FY27
- Thyrocare aims for specialty diagnostics (allergy, genomics, etc.) to constitute 15-20% of its total portfolio revenue within 3-5 years from Q1FY27 — 15% to 20%, three to five year timeline
- No significant capex is anticipated for the specialty diagnostics business in FY28 (next year from Q1FY27) — FY28
- The divestment process for the radiology (Nuclear Healthcare) business is expected to take about 6 months from July 2026, i.e., by approximately January 2027 — 6 months, Q4FY27
- API Holdings (parent) expects to become profitable excluding Thyrocare and debt-free in approximately 12 months from July 2026 (i.e., by Q2FY28), after which an IPO may be considered — Q2FY28
- Thyrocare will announce its branded consumables initiative by September 2026 — Q2FY27
- ESOP charge is expected to stabilise around ₹3.5 Cr per quarter going forward — ₹3.5 Cr
Key themes
Franchisee expansion and specialty diagnostics launch
How the narrative shifted
- Franchisee network scaling: Aggressive franchisee additions supported by expanded field team, brand ambassador, and deeper geographic penetration, promising sustained volume growth.
- Specialty diagnostics foray: Launch of allergy and genomics leverages existing central-lab infrastructure and affordable-pricing philosophy to tap underpenetrated specialist market.
- Affordable diagnostics mission: Reiterated commitment to low-cost, high-quality diagnostics as the fundamental driver of market share, even in specialty where pricing will be disruptive.
- Radiology divestment and capital discipline: Exiting dilutive nuclear imaging business to sharpen focus on high-ROC pathology; disciplined capital allocation highlighted.
- Parent company deleveraging: API Holdings debt reduced to ₹1,050 Cr; IPO/corporate action only after standalone profitability and zero debt, at least 12 months away, removing near-term overhang.
- Digital and operational excellence: Investments in AI, automation, and NABL accreditation reinforce quality perception and operational efficiency, underpinning franchisee trust.
Operational commentary
- Added 900 net new franchisees in Q1, taking total active franchisees to 11,700; field team doubled to ~70; brand ambassador Madhuri Dixit supporting franchise recruitment
- Specialty diagnostics business commercially launched with allergy (Phadia platform) and genomics (NIPT, exome sequencing, gut microbiome, etc.), supported by dedicated medical and commercial team
- Opened 3 new labs in Muzaffarpur, Kurnool, and Prayagraj; total lab network now 44 (43 India + 1 Tanzania)
- Home collection phlebotomist network at 2,100+, with 99% on-time arrival; turnaround time improved to 3.37 hours; complaint management at 3.1 per million tests (Six Sigma level)
- Test menu expanded to over 1,375 tests; all own labs NABL accredited; 100+ MD Pathologists
- Radiology divestment process initiated for Nuclear Healthcare; management expects ~6 months to complete; FY27 radiology PAT seen at ~₹6 Cr on investment of ~₹140 Cr
- Aarogyam brand grew 21% YoY, Jaanch grew 36% YoY; revenue-per-vial improved as semi-specialized test mix shifted away from low-value thyroid towards biochemistry/markers
- Rahul Guha highlighted 5-year transformation: franchise base quadrupled, lab network 17 to 44, test menu 5x, ROCE improved from 15% to 34%, EBITDA margin from 23% to 32%
Analyst Q&A
Q. Specialty diagnostics contribution in next 3-4 years and capex requirement
Ambition to reach 15-20% of portfolio in 3-5 years; most capex already done at central labs, no significant capex next year
Q. Revised annual franchisee addition target after 900 adds in Q1
Expect 500-700 adds per quarter (barring Q3); full-year net adds around 1,700, after accounting for churn; too early to revise formal target
Q. API Holdings debt and IPO plans; promoter pledge
Debt reduced to ₹1,050 Cr from ₹1,800 Cr; no IPO plans until API ex-Thyrocare is profitable and debt-free, at least 12 months away; selling non-strategic assets to reduce debt
Q. Status of entry into consumables space
Will be Thyrocare branded consumables, not backward integration; announcement by September; asked for patience
Q. Financial impact and rationale of radiology divestment
Nuclear business not growing, no fresh investment; investment ~₹140 Cr, PAT ~₹6 Cr expected for FY27; process to find partner in 6 months
Research and educational content only. Not investment advice.